Clinical Trial Update: Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis [Phase 4]

View source ↗

Summary

This clinical trial update concerns ocrelizumab discontinuation in relapsing multiple sclerosis, with a Phase 4 study currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (Ocrevus) (ocrelizumab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Multiple Sclerosis | Phase 4 | Status: RECRUITING